Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results
March 04, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
– FDA accepts resubmitted NDA for VP-102 for the treatment of molluscum contagiosum with PDUFA goal date of June 23, 2021 – – Verrica Announces Torii Pharmaceutical Has Exercised Option to...
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference
March 03, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., March 03, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference
February 23, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
February 17, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
- PDUFA goal date assigned is June 23, 2021 - - VP-102 (cantharidin 0.7% Topical Solution) could potentially be the first FDA-approved treatment for molluscum contagiosum, a highly contagious...
Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference
January 19, 2021 07:00 ET
|
Verrica Pharmaceuticals Inc.
- In new post hoc analyses of the Phase 3 molluscum trials segmenting molluscum lesions by body region and study visit, the percentage of participants with complete clearance of all baseline and new...
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
December 23, 2020 16:01 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces Receipt of Final FDA Minutes Following Type A Meeting Regarding Resubmission of the NDA for VP-102 in Molluscum
November 17, 2020 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Penn., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual London Healthcare Conference
November 12, 2020 16:05 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts (CARE-1)
November 10, 2020 07:30 ET
|
Verrica Pharmaceuticals Inc.
- 35% of subjects treated with VP-102 achieved complete clearance of all treatable genital warts vs 2.4% for vehicle (p=0.0001) - - VP-102 was well-tolerated with no reported serious adverse events...
Verrica Pharmaceuticals Reports Third Quarter 2020 Financial Results
November 09, 2020 07:30 ET
|
Verrica Pharmaceuticals Inc.
- Verrica completes Type A meeting and expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 - WEST CHESTER, Penn., Nov. 09,...